Lassa fever vaccine candidates: A scoping review of vaccine clinical trials.
LASV
clinical trial
priority pathogens
vaccine candidate
vaccine development
viral haemorrhagic fever
Journal
Tropical medicine & international health : TM & IH
ISSN: 1365-3156
Titre abrégé: Trop Med Int Health
Pays: England
ID NLM: 9610576
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
pmc-release:
01
06
2024
medline:
5
6
2023
pubmed:
25
4
2023
entrez:
25
04
2023
Statut:
ppublish
Résumé
Lassa fever (LF) is caused by a viral pathogen with pandemic potential. LF vaccines have the potential to prevent significant disease in individuals at risk of infection, but no such vaccine has been licensed or authorised for use thus far. We conducted a scoping review to identify and compare registered phase 1, 2 or 3 clinical trials of LF vaccine candidates, and appraise the current trajectory of LF vaccine development. We systematically searched 24 trial registries, PubMed, relevant conference abstracts and additional grey literature sources up to 27 October 2022. After extracting key details about each vaccine candidate and each eligible trial, we qualitatively synthesised the evidence. We found that four LF vaccine candidates (INO-4500, MV-LASV, rVSV∆G-LASV-GPC, and EBS-LASV) have entered the clinical stage of assessment. Five phase 1 trials (all focused on healthy adults) and one phase 2 trial (involving a broader age group from 18 months to 70 years) evaluating one of these vaccines have been registered to date. Here, we describe the characteristics of each vaccine candidate and trial and compare them to WHO's target product profile for Lassa vaccines. Though LF vaccine development is still in early stages, current progress towards a safe and effective vaccine is encouraging.
Identifiants
pubmed: 37095630
doi: 10.1111/tmi.13876
pmc: PMC10247453
mid: NIHMS1896702
doi:
Substances chimiques
Viral Vaccines
0
Types de publication
Systematic Review
Journal Article
Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
420-431Subventions
Organisme : NIAID NIH HHS
ID : R01 AI132496
Pays : United States
Informations de copyright
© 2023 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
Références
Lancet. 2023 Apr 15;401(10384):1267-1276
pubmed: 36934733
BMJ Glob Health. 2021 Oct;6(10):
pubmed: 34635552
BMJ. 2003 Nov 29;327(7426):1271-5
pubmed: 14644972
BMJ. 1988 Sep 3;297(6648):584-7
pubmed: 3139220
Curr Opin Virol. 2019 Aug;37:105-111
pubmed: 31472333
Emerg Infect Dis. 2019 May;25(5):1026-1027
pubmed: 30807268
Curr Top Microbiol Immunol. 2002;262:75-109
pubmed: 11987809
Virus Genes. 2017 Oct;53(5):733-740
pubmed: 28710608
Nat Commun. 2021 Oct 1;12(1):5759
pubmed: 34599162
Otolaryngol Head Neck Surg. 1992 Mar;106(3):226-9
pubmed: 1589210
Lancet. 1979 Oct 6;2(8145):738
pubmed: 90819
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
Lancet Infect Dis. 2019 Dec;19(12):1371-1378
pubmed: 31588039
Vaccines (Basel). 2022 Oct 06;10(10):
pubmed: 36298533
J Med Virol. 2021 Dec;93(12):6433-6436
pubmed: 34289134
NPJ Vaccines. 2018 Mar 20;3:11
pubmed: 29581897
J Vector Borne Dis. 2007 Mar;44(1):1-11
pubmed: 17378212
Open Forum Infect Dis. 2019 Dec 03;6(12):ofz512
pubmed: 31879673
J Virol. 2000 Aug;74(15):6992-7004
pubmed: 10888638
PLoS Comput Biol. 2021 Mar 3;17(3):e1008811
pubmed: 33657095
Nat Commun. 2023 Mar 11;14(1):1352
pubmed: 36906645
Epidemiol Rev. 2019 Jan 31;41(1):28-33
pubmed: 31673694
Acta Biomater. 2018 Oct 15;80:31-47
pubmed: 30172933
J Virol. 2014 May;88(9):4897-907
pubmed: 24554655
Nat Commun. 2022 Sep 27;13(1):5596
pubmed: 36167835
Int J Infect Dis. 2020 Nov;100:82-87
pubmed: 32795603
Vaccine. 2017 Jul 24;35(33):4064-4071
pubmed: 28647170
Hum Vaccin Immunother. 2013 Oct;9(10):2246-52
pubmed: 24051434
Lancet. 2023 Apr 15;401(10384):1242-1243
pubmed: 36934735
Expert Rev Vaccines. 2013 Jan;12(1):71-86
pubmed: 23256740
Nat Rev Microbiol. 2023 Feb;21(2):87-96
pubmed: 36097163
PLoS Med. 2005 Jun;2(6):e183
pubmed: 15971954
PLoS Negl Trop Dis. 2015 Apr 17;9(4):e0003736
pubmed: 25884628
Infez Med. 2022 Mar 1;30(1):30-40
pubmed: 35350264
Bull World Health Organ. 2021 Jul 1;99(7):479-479A
pubmed: 34248217
Hum Gene Ther Methods. 2012 Jun;23(3):157-68
pubmed: 22794496
N Engl J Med. 2018 Nov 1;379(18):1745-1753
pubmed: 30332564
Cell Rep. 2022 Jul 19;40(3):111094
pubmed: 35858566
Drug Des Devel Ther. 2018 Aug 14;12:2519-2527
pubmed: 30147299
Immunol Lett. 2019 Nov;215:1-11
pubmed: 31026485
Hum Vaccin Immunother. 2019;15(10):2269-2285
pubmed: 31368826
Infect Dis Clin North Am. 2019 Dec;33(4):933-951
pubmed: 31668199
J Infect Dis. 1987 Mar;155(3):445-55
pubmed: 3805772
J Clin Invest. 2020 Jan 2;130(1):539-551
pubmed: 31820871
Emerg Infect Dis. 2006 Dec;12(12):1971-4
pubmed: 17326956
Heliyon. 2021 Sep;7(9):e07972
pubmed: 34541362
Signal Transduct Target Ther. 2021 Feb 2;6(1):48
pubmed: 33531462